Solifenacin 5/10 mg tabs — $0 with Membership

Related medications

Other medications associated with the same conditions in this catalog.

Also listed for Overactive Bladder / Urge Incontinence

• Oxybutynin
• Tolterodine
• Oxybutynin 5 mg tabs
• Tolterodine 1/2 mg tabs

About Solifenacin 5/10 mg tabs

Experiencing the frequent, sudden urge to go? Solifenacin 5 and 10 mg tablets are a common and effective prescription medication designed to help manage the disruptive symptoms of overactive bladder. With TheDrugClub, you can access this vital treatment without the financial burden, often enjoying significant savings and even $0 co-pays for members looking for relief.

Overactive bladder (OAB) can significantly impact daily life, leading to frequent trips to the restroom, sudden urges, and even accidental leakage. It's a condition characterized by involuntary contractions of the bladder muscle, even when the bladder isn't full. This is where Solifenacin 5 mg and 10 mg tablets come into play.

What Solifenacin Treats

Solifenacin is primarily prescribed to treat the symptoms of overactive bladder. These symptoms include urinary urgency (a sudden, compelling need to pass urine that is difficult to defer), urinary frequency (having to urinate more often than usual), and urge incontinence (involuntary loss of urine associated with a sudden, strong desire to urinate). By addressing these issues, Solifenacin helps patients regain control over their bladder function and improve their quality of life.

How Solifenacin Works

Solifenacin belongs to a class of medications called antimuscarinics. It works by blocking the action of acetylcholine, a natural chemical messenger in the body that plays a crucial role in bladder muscle contraction. Specifically, Solifenacin targets muscarinic receptors in the bladder. By blocking these receptors, it helps to relax the detrusor muscle (the muscle that contracts to empty the bladder) and increase the bladder's capacity to hold urine. This reduction in involuntary bladder contractions leads to fewer sudden urges and less frequent urination, helping to alleviate the disruptive symptoms of OAB.

Typical Costs of Solifenacin

Without insurance or discount programs, the cost of Solifenacin can be a significant barrier for many. A month's supply of Solifenacin 5 mg or 10 mg can typically range from $200 to over $400, depending on the pharmacy, dosage, and whether it's a brand-name or generic version. These high out-of-pocket expenses can make consistent treatment difficult, forcing many to choose between their health and other essential needs.

Get Solifenacin for a $0 Co-pay with TheDrugClub

At TheDrugClub, we believe that managing your health shouldn't break the bank. We understand the financial strain that prescription costs can place on individuals and families. That's why we've made it our mission to provide affordable access to essential medications like Solifenacin.

As

The information above is for educational purposes only and does not constitute medical advice. Consult your healthcare provider before making medication decisions.

What Solifenacin 5/10 mg tabs is approved for (FDA label)

Solifenacin succinate is indicated for the treatment of adults with overactive bladder with symptoms of urge urinary incontinence, urgency, and urinary frequency. Solifenacin succinate is a muscarinic antagonist indicated for the treatment of adults with overactive bladder with symptoms of urge urinary incontinence, urgency, and urinary frequency. ( 1 )

Source: Read the full FDA label on DailyMed. Label effective date: July 6, 2026.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Dosage forms and strengths for Solifenacin 5/10 mg tabs (FDA label)

The 5 mg tablets are white or almost white round film-coated tablets, debossed with “C2” on one side and blank on the other side. The 10 mg tablets are white or almost white round film-coated tablets, debossed with “C77” on one side and blank on the other side. Tablets: 5 mg and 10 mg. ( 3 )

Source: FDA prescribing information (DailyMed). Set ID: 56026679-4002-a6c6-e063-6294a90a7b55. SPL document ID: 55fc3fe5-e340-3480-e063-6394a90a1092. Label effective date: July 6, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Adverse reactions for Solifenacin 5/10 mg tabs (FDA label)

The most common adverse reactions (> 4% in Solifenacin succinate tablets-treated patients and > placebo-treated patients) were dry mouth and constipation at both 5 mg and 10 mg doses; and urinary tract infection and blurred vision at the 10 mg dose. ( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact HEC Pharm USA Inc. at 1-800-610-5709 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch . 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

Source: FDA prescribing information (DailyMed). Set ID: 56026679-4002-a6c6-e063-6294a90a7b55. SPL document ID: 55fc3fe5-e340-3480-e063-6394a90a1092. Label effective date: July 6, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Contraindications for Solifenacin 5/10 mg tabs (FDA label)

Solifenacin succinate is contraindicated in patients: With urinary retention [see Warnings and Precautions ( 5.2 )] , With gastric retention [see Warnings and Precautions ( 5.3 )] , With uncontrolled narrow-angle glaucoma [see Warnings and Precautions ( 5.5 )] , and Who have demonstrated hypersensitivity to solifenacin succinate or the inactive ingredients in Solifenacin succinate tablets. Reported adverse reactions have included anaphylaxis and angioedema [see Adverse Reactions ( 6.2 )] . Urinary retention. ( 4 , 5.2 ) Gastric retention. ( 4 , 5.3 ) Uncontrolled narrow-angle glaucoma. ( 4 , 5.5 ) Hypersensitivity to this product or any of its components. ( 4 , 5.1 , 6.2 )

Source: FDA prescribing information (DailyMed). Set ID: 56026679-4002-a6c6-e063-6294a90a7b55. SPL document ID: 55fc3fe5-e340-3480-e063-6394a90a1092. Label effective date: July 6, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Warnings and precautions for Solifenacin 5/10 mg tabs (FDA label)

Angioedema and Anaphylactic Reactions : Promptly discontinue Solifenacin succinate tablets and provide appropriate therapy. ( 5.1 ) Urinary Retention : Solifenacin succinate tablets are not recommended for use in patients with clinically significant bladder outlet obstruction. ( 5.2 ) Gastrointestinal Disorders : Solifenacin succinate tablets are not recommended for use in patients with decreased gastrointestinal motility. ( 5.3 ) Central Nervous System Effects : Somnolence has been reported with solifenacin succinate.

Source: FDA prescribing information (DailyMed). Set ID: 56026679-4002-a6c6-e063-6294a90a7b55. SPL document ID: 55fc3fe5-e340-3480-e063-6394a90a1092. Label effective date: July 6, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Drug interactions for Solifenacin 5/10 mg tabs (FDA label)

CYP3A4 Inhibitors : Do not exceed the 5 mg dose of Solifenacin succinate tablets with concomitant use of strong CYP3A4 inhibitors. ( 7.1 ) 7.1 Strong CYP3A4 Inhibitors Solifenacin is a substrate of CYP3A4. Concomitant use of ketoconazole, a strong CYP3A4 inhibitor, significantly increased the exposure of solifenacin [see Clinical Pharmacology ( 12.3 )] . The dosage of Solifenacin succinate tablets greater than 5 mg once daily is not recommended when concomitantly used with strong CYP3A4 inhibitors [see Dosage and Administration ( 2.4 )] .

Source: FDA prescribing information (DailyMed). Set ID: 56026679-4002-a6c6-e063-6294a90a7b55. SPL document ID: 55fc3fe5-e340-3480-e063-6394a90a1092. Label effective date: July 6, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.